ABSTRACT
The beta-adrenoblockers anapriline and visken and the calcium antagonist corinfar were studied for effects on the atherogenic properties of the sera from patients with coronary heart disease who took the drugs. The study was performed by using cultured atherosclerotically altered human aortic smooth muscle cells. A single dose of anapriline, 80 mg, and that of visken, 20 mg, were found to give rise to or to enhance atherogenic properties of the patients' sera, while that of corinfar, 20 mg, yielded their antiatherosclerotic properties.
Subject(s)
Coronary Disease/blood , Nifedipine/pharmacology , Pindolol/pharmacology , Propranolol/pharmacology , Adult , Cells, Cultured , Coronary Disease/drug therapy , Humans , Male , Middle Aged , Muscle, Smooth, Vascular , Nifedipine/therapeutic use , Pindolol/therapeutic use , Propranolol/therapeutic useABSTRACT
In most patients with coronary heart disease (CHD) and angiographically documented stenosed 1-3 coronary arteries, serum contained cholesterol (C) in the circulating immune complexes (CIC), cholesterol levels in these complexes being directly related to serum atherogenicity, i.e. to their ability to cause a 2-5-fold accumulation of lipids in cultured smooth muscle cells (SMC) of the uninvolved human aortic intima (r = 0.91). Removal of IgG and IgM from the patients' sera led to a 75 and 37% decrease, respectively, in their atherogenic properties displayed in cultured SMC. Much more decrease in the atherogenic potential of the sera was seen in 2.5% polyethylene glycol-induced precipitation of CIC. At the same time, incubation of human aortic intimal SMC with CIC isolated from the atherogenic sera from CHD patients caused a 1.5-3-fold increase in intracellular C levels. It was suggested that CIC cholesterol was a determinant of atherogenicity of the sera from patients with coronary atherosclerosis.
